Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pituitary Dwarfism Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Chromosome 18 Clinical Research Center

NCT00227253
View directory record Official record
Conditions
Chromosome Aberrations, Growth Hormone Deficiency, Hypomyelination
Interventions
Determination of growth hormone status, Measurement of growth, thyroid and sex hormone levels, Behavior and neuropsychometric evaluations, Audiological and ear, nose and throat examination, Magnetic resonance imaging of the brain, Dysmorphology evaluation, Neurology examination, Dental evaluation, Speech pathology evaluation, Psychiatric evaluation, Orthopedic evaluation, Ophthalmologic evaluation, Gastrointestinal evaluation
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2040
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

Pharmacodynamics of CNP During Growth Hormone Treatment

NCT01504802
View directory record Official record
Conditions
Pituitary Dwarfism, Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy

NCT00711061
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 4 Interventional Results available

A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

NCT02311894
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
3 Years to 14 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

VRS-317 in Adult Subjects With Growth Hormone Deficiency

NCT01359488
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Jul 23, 2026, 2:45 AM EDT
Not listed Not applicable Interventional

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

NCT01804413
View directory record Official record
Conditions
Adults Growth Hormone Deficiency.
Interventions
Pegvisomant, Regular insulin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Jul 23, 2026, 2:45 AM EDT
Recruiting Phase 3 Interventional

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851
View directory record Official record
Conditions
Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Palo Alto, California • Sacramento, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 1Phase 2 Interventional

Versartis Trial in Children to Assess Long-Acting Growth Hormone

NCT01718041
View directory record Official record
Conditions
Pediatric Growth Hormone Deficiency
Interventions
Experimental: VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Clovis, California • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD

NCT02988687
View directory record Official record
Conditions
Adult-Onset Growth Hormone Deficiency
Interventions
Not listed
Lead sponsor
Garcia, Jose M., MD, PhD
Individual
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

NCT02968004
View directory record Official record
Conditions
Pediatric Growth Hormone Deficiency
Interventions
MOD-4023, Somatropin
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Orange, California • Aurora, Colorado • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency

NCT00489294
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Syntropin
Drug
Lead sponsor
Phage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2012 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

NCT01502124
View directory record Official record
Conditions
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
21
States / cities
Los Angeles, California • Wilmington, Delaware • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Versartis International Trial in Adults With Long-Acting Growth Hormone

NCT02526420
View directory record Official record
Conditions
Adult Growth Hormone Deficiency
Interventions
somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
23 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Escondido, California • Laguna Hills, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.

NCT00448747
View directory record Official record
Conditions
Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Interventions
AEZS-130 (formerly ARD-07), L-ARG+GHRH
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
13
States / cities
Tempe, Arizona • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

NCT02229851
View directory record Official record
Conditions
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions
somapacitan, somatropin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
23 Years to 79 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

NCT02580032
View directory record Official record
Conditions
Growth Disorder, Growth Hormone Deficiency in Children
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
4 Years to 13 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Centennial, Colorado • Wilmington, Delaware + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency

NCT01007071
View directory record Official record
Conditions
Hypopituitarism
Interventions
Human Growth Hormone (1-134), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jul 23, 2026, 2:45 AM EDT
Enrolling by invitation No phase listed Observational

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

NCT05718570
View directory record Official record
Conditions
Adult Growth Hormone Deficiency
Interventions
Somapacitan
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

NCT03831880
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Genotropin, somatrogon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Sacramento, California • Aurora, Colorado • Centennial, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

NCT03225755
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth hormone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

NCT05250063
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
LUM-201
Drug
Lead sponsor
Lumos Pharma
Industry
Eligibility
3 Years to 13 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
San Diego, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

National Cooperative Growth Study in CKD

NCT00616278
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
1 Day to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

NCT01009905
View directory record Official record
Conditions
Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 18 Years
Enrollment
22,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy

NCT04938466
View directory record Official record
Conditions
Growth Hormone Deficiency, Growth Hormone Treatment
Interventions
Long-Acting Growth Hormone (LAGH)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
2 Years to 13 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 23, 2026, 2:45 AM EDT